We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

The Fanconi Anemia Pathway of DNA Repair and Human Cancer

Vaidehi Krishnan, Lavina Sierra Tay and Yoshiaki Ito

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/59995>

1. Introduction

The accurate repair of DNA damage and the maintenance of genomic integrity is a fundamental property of every cell. Amongst the different classes of DNA damaging agents, DNA interstrand crosslinks (ICLs) represent a class of DNA lesions wherein the two strands of DNA get cross-linked by covalent bonds. Unrepaired, such cross-linking will impede the progress of critical processes like DNA replication and transcription, resulting in a genomic instability-associated disorder called, Fanconi Anemia (FA).

Fanconi anemia is a rare genetic disorder that occurs at the frequency of 1 in 1:100,000 births. The clinical features of Fanconi anemia were first described by the Swiss paediatrician, Guido Fanconi, in the year 1927. The disease is characterized by low birth weight, developmental defects like congenital limb deformities, hearing failure, skin hyperpigmentation, gastrointestinal abnormalities and haematological defects like aplastic anemia, myelodysplastic syndrome (MDS) and bone marrow failure (BMF). During their life time, Fanconi anemia patients have a very high risk for developing leukemias and solid tumors, due to underlying genomic instability.

At the cellular level, cells deficient in the Fanconi anemia pathway show acute sensitivity to DNA interstrand crosslinking agents and the accumulation of chromosomal aberrations. This chapter will focus on the molecular mechanism underlying the Fanconi anemia pathway of ICL repair and the role this pathway plays in preventing human cancer.

2. Molecular control of ICL repair by the FA pathway

The FA pathway of DNA repair is activated when the DNA replication forks are stalled and they encounter an interstrand crosslinked DNA in the S phase of cell cycle. Human FA is caused by mutations in 16 FA gene products, identified so far. A central molecular event in the FA pathway is the monoubiquitination of FANCD2 at lysine 561 and FANCI at lysine 523, a process mediated by the FA core complex. The FA core complex (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL and FANCM) is a multi-subunit ubiquitin ligase. Mutations in any of the constituting subunits cause impaired ICL repair and FA. Upon monoubiquitination, FANCD2 recruits the nucleases, FAN1 and SLX4 (FANCP), which together with XPF/ERCC4 (FANCP) incise on either side of the crosslink. Finally, homologous recombination (HR) repair by the DNA repair proteins FANCD1 (BRCA2), FANCN (PALB2), FANCF (BRIP1) and FANCO (RAD51C) in conjunction with translesion repair restore the fidelity of the original DNA double helix. Apart from above described bonafide FA genes, there is a growing list of FA-core complex associated proteins, such as FAAP20, FAAP24, FAAP100, MHF1, MHF2, USP1, and S phase checkpoint proteins like ATR and CHK1. As yet, mutations in such accessory proteins have not been uncovered in FA patients, but, they are nevertheless important in controlling the various steps of the repair process. *In the first section of this chapter, the molecular regulation of the Fanconi anemia (FA) pathway of DNA repair will be discussed.*

2.1. Replication-coupled interstrand crosslink repair

DNA interstrand crosslinking occurs when nucleotides on opposing DNA strands undergo a covalent linkage. The resultant crosslinked DNA poses a physical impediment for the movement of the DNA replication and transcription apparatus. Hence, ICL agents are highly toxic and it is estimated that even 1-2 crosslinks can be lethal in repair-deficient yeast strains [1]. Chemicals such as mitomycin C, cisplatin, diepoxybutane, metabolic by-products like acetaldehyde, formaldehyde, malondialdehyde and acrolein containing electrophilic groups are capable of causing DNA interstrand crosslinking.

In seminal work by Raschle *et al*, an elegant cell-free repair assay with *Xenopus* egg extracts was used to elucidate the exact order of events during ICL repair [2]. A plasmid containing a crosslink was mixed with *Xenopus* egg extracts and DNA repair was monitored. In this model, two opposing forks collide with crosslinked DNA to activate ICL repair. It was observed that as the leading strand of a replication fork approaches a crosslink, it pauses at the distance of 20-40 nucleotides from the crosslink due to a block posed by the MCM helicase that traverses ahead of the moving replication fork. The 5' end of the lagging strand also stalls at variable distance from the crosslink. The nascent leading strand that has paused at 20-40 nucleotides then advances to within one nucleotide distance of the ICL after the eviction of the stalled-MCM helicase by BRCA1 [3]. Dual incisions follow that cut on either end of the crosslinked oligonucleotide, to mediate the 'unhooking' step. This reaction then generates two sister chromatids with different kinds of DNA lesions: one sister chromatid contains the crosslink whereas the other sister chromatid has a break. The sister chromatid carrying the crosslink is repaired by translesion polymerases that bypass the crosslink. On the other hand, the broken

sister chromatid is repaired by RAD51-dependent strand invasion into the repaired DNA strand.

This cell-free assay was used to demonstrate that the FA core complex-dependent FANCI/FANCD2 monoubiquitination is a critical step for mediating the nucleolytic incisions and translesion synthesis past the lesion. Also, it was shown that recombination acts downstream of the FANCI/FANCD2 loading step [4, 5].

DNA ICL repair can be subdivided mechanistically into the following key steps: Recognition of lesion, FA core complex-mediated FANCI/FANCD2 monoubiquitination, crosslink unhooking, lesion bypass by translesion synthesis of the sister chromatid carrying the excised nucleotide and HR repair of broken sister chromatid (Figure.1 and Figure.2).

2.2. Recognition of lesion

A stabilized DNA replication intermediate consisting of an ICL-bound stalled-replication fork acts as that activating signal for the FA pathway of repair [6]. Since most of the FA core complex proteins lack recognizable functional domains, the proteins involved in FA pathway activation and lesion recognition remained a mystery until the discovery of FANCM.

One of the first proteins capable of recognising the ICL-bound stalled-replication fork is the FANCM-FAAP24-MHF1 complex. FANCM is a large 230 kDa protein, which complexes with FAAP24 through its C-terminal domain. The FANCM-FAAP24 complex binds to synthetic substrates like ssDNA, splayed arm, and 3'-flap DNA structure, which mimic intermediates during replication or repair [7]. FANCM has a functional DEAH-type helicase domain with DNA-dependent ATPase activity and it translocates on dsDNA in an ATPase-dependent manner to promote the migration of Holliday branches and replication fork branch points [8] [9] [10]. FANCM-dependent translocation stimulates the accumulation of RPA, the ssDNA binding protein [11]. In turn, RPA recruitment is required for ATR loading and activation of the ATR-dependent checkpoint. Thus, the depletion of FANCM or FAAP24 causes defective ATR-mediated checkpoint signalling leading to impaired CHK1, p53 and FANCE phosphorylation after DNA damage [12] [13]. FANCM and FAAP24 also regulate FA core complex relocalization to chromatin during ICL repair. Hence, the depletion of FANCM or FAAP24 with SiRNA cause impaired FANCD2 monoubiquitination and FANCD2 focus formation [14].

Unlike the other FA core complex proteins, FANCM and FAAP24 are constitutively localised on chromatin through their interaction with the histone-fold containing complex MHF1 and MHF2. The MHF complex stimulates DNA binding and replication fork remodelling by FANCM. The depletion of MHF1 or MHF2 caused the destabilization of FANCM, impaired chromatin localization of the FA core complex, reduced FANCD2 monoubiquitination and focus formation and resulted in the accumulation of chromosomal aberrations [15] [16]. Recent structural studies have revealed that the MHF complex senses branched DNA by binding to a pair of crossover DNA duplexes providing mechanistic insights on how the MHF complex stimulates FANCM translocation activity at such a DNA structure [17].

Figure 1. Major steps of the DNA Interstrand crosslink repair pathway

2.3. Role of ATR in ICL repair

ATR or Ataxia telangiectasia mutated related is a master regulator of the S-phase checkpoint. In response to different classes of DNA replication stresses, ATR activation is dependent on the presence of RPA-coated single-stranded DNA (ssDNA) containing regions [18]. ATR coordinates checkpoint activation with the completion of DNA repair by phosphorylating CHK1. Defective ATR function results in crosslinker hypersensitivity, impaired FANCD2 monoubiquitination and the accumulation of massive genomic instability in the form of radial chromosomes [19, 20].

Many FA proteins undergo phosphorylation by ATR and these phosphorylation events are necessary for a functional FA pathway. ATR phosphorylates FANCD2 at threonine 691 and serine 717, at clustered SQ/TQ (serine/threonine-glutamine) motifs on FANCI and at ser 1449 on FANCA. In response to replication stress, CHK1 is also activated by ATR and it directly phosphorylates FANCE subunit at threonine 346 and serine 347. All these phosphorylation events are essential for FANCD2 monoubiquitination [21-24]. Interestingly, FANCM which is implicated in ATR activation, itself undergoes ATR-dependent ser 1025 phosphorylation. FANCM phosphorylation at this site controls integrity of the FA pathway, prevents premature mitotic entry and is required for ATR-dependent checkpoint activation [25]. These data

Figure 2. Integrated view of how FA proteins orchestrate the various steps of ICL repair FA core proteins are depicted in blue, FA accessory proteins are indicated in beige and FA downstream proteins involved in homologous recombination are indicated in pink. Step 1: Crosslink Recognition, Step 2: FANCI and FANCD2 monoubiquitination by the FA core complex, Step 3: Recruitment of Ub-FANCD2 and FA downstream proteins, Step 4: Completion of DNA repair by translesion synthesis and homologous recombination.

indicate the existence of a feedback loop wherein the initial signal constituting the ICL-bound stalled-replication fork is recognised by FANCM, which activates ATR. In turn, ATR phosphorylates a number of substrates such as FANCA, FANCI, FANCD2 and lastly FANCM itself, triggering the complete activation of the FA pathway that leads to FANCD2 monoubiquitination.

2.4. The FA core complex

Historically, FA complementation groups were assigned after the pair-wise fusion of patient-derived cell lines followed by assessment of crosslinker sensitivity. Genes mutated in each complementation group were cloned and re-introduced back into mutant cell lines and the ability to rescue crosslinker sensitivity was assessed. Based on this analysis, about 80% of Fanconi anemia patients were assigned to the subtypes FANCA or FANCC [26].

Using a combination of techniques like immunoprecipitation and immunofluorescence, some FA proteins were found to associate to each other, leading to the concept of a FA core complex [27]. It is now known that the FA core complex is constituted by a group proteins mutated in

FA like FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM and the accessory proteins FAAP24, FAAP20 and FAAP100. Out of these subunits, FANCL, which is a RING domain-containing protein, has the ubiquitin ligase E3 subunit. Proper assembly of the core complex is necessary for FANCI and FANCD2 monoubiquitination reaction. Importantly, patient-derived mutations that disrupt the structural integrity of the FA core complex compromise ICL repair [27].

The assembly of the FA core complex depends on protein-protein interactions between the components. One of the first interactions reported between FA core complex proteins was the binding between FANCA and FANCC [28]. FANCA also interacts with FANCL and this interaction is dependent on FANCG, FANCB and FANCM. FANCB interacts with FANCL and a complex of these proteins binds FANCA [29]. FANCE interacts with FANCD2 [30] and FANCG interacts with FANCA [31, 32]. FANCC nuclear localization depends on interaction with FANCE and FANCA requires nuclear localization of FANCC [34].

The accessory protein, FAAP100 is essential for the stability of the core complex and directly interacts with FANCB and FANCL to form a stable sub complex [35]. Another accessory protein, FAAP20 binds to FANCA and ensures the functional integrity of the FA core complex. The depletion of FAAP20 causes hypersensitivity to crosslinking agents, chromosomal aberrations and reduces FANCD2 monoubiquitination [36].

Recently, a modularised organisation has been ascribed for the FA core complex and the catalytic module composed of the FANCL-FANCB-FAAP100 proteins was identified as the minimal subcomplex essential for the ubiquitin ligase function [37]. On the other hand, the other two modules composed of FANCA, FANCG, FAAP20 module and FANCC, FANCE, FANCF modules were proposed to provide non-redundant functions that facilitate the catalytic module to bind sites of DNA damage [38].

2.5. The FANCD2/FANCI complex

A major conundrum in the FA field was solved with the discovery that the FA core complex monoubiquitinates FANCD2 (Ub-FANCD2) at lysine 561 [39]. FANCD2 monoubiquitination is DNA damage-dependent and Ub-FANCD2 localizes to sites of DNA damage to form FANCD2 nuclear foci.

Since most of the FA core proteins described above lacked any enzymatic domain, the next big search was for the FANCD2 ubiquitin ligase that catalyses the monoubiquitination reaction. FANCL was later identified as the key ubiquitin ligase responsible for catalysing the monoubiquitination of FANCD2 [40]. It was the only protein with known enzymatic activity in the form of a ubiquitin ligase activity and it contained a PHD-type ring finger at the C terminal domain and an RWD (RING finger proteins, WD-repeat proteins, and yeast DEAD-like) domain responsible for substrate binding [41-43]. The PHD domain of FANCL interacts with the ubiquitin conjugating enzyme, UBE2T. As expected, UBE2T-depleted cells accumulate abnormal radial chromosomes due to impaired FANCD2 monoubiquitination and defective ICL repair [44]. UBE2T itself undergoes monoubiquitination and inactivation after DNA damage, in a process stimulated by FANCL. Thus, UBE2T was identified as the E2 of the FA

pathway and it was proposed that UBE2T has a self-inactivation mechanism that is important for the negative regulation of the FA pathway.

The identity of the protein responsible for Fanconi complementation group I solved another missing link in the FA field. FANCI was identified as a protein essential for FANCD2 monoubiquitination [45-47]. FANCI is a FANCD2 paralogue and it heterodimerizes with FANCD2 to form the so-called FANCI/FANCD2 complex or the ID complex [45]. Just like FANCD2, FANCI also undergoes monoubiquitination and surprisingly, the monoubiquitination of both proteins are inter-dependent on each other, which suggested a unique regulation for ubiquitin conjugation. Upon treatment with crosslinking agents, both FANCI and FANCD2 form nuclear foci. The solved crystal structure of FANCI and FANCD2 revealed a saxophone-shaped crystal structure, with single-strand and double-strand binding regions, indicating that the complex can bind to DNA structures that arise after replication forks encounter crosslinking lesions [48]. Surprisingly, the FANCI/FANCD2 regulatory and monoubiquitination sites mapped to the interface of FANCI/FANCD2 binding. In order to explain how the ubiquitin ligase can access the buried ubiquitination site, it was proposed that the monoubiquitination reaction probably acted on monomeric proteins [48].

When the binding activity of the ID complex was tested towards several DNA substrates, it was found that ID complex had better affinity for branched substrates such as splayed arm, Holliday junction, 5'-flap, 3'-flap and static fork structures as compared to simple dsDNA, ssDNA or 5'-tailed or 3'-tailed structures [49]. Recently, using purified proteins it has been shown that the ID complex is a poor substrate for ubiquitination by UBE2T and FANCL, unless branched or duplex DNA is added to the reaction. Also, mutations in FANCI that inhibit its DNA binding also prevent FANCD2 monoubiquitination. Conversely, FANCI can undergo the monoubiquitination reaction, in a manner independent of FANCD2 [50, 51]. Using *Xenopus* egg extracts, it was proposed that the ID complex might represent the inactive form and monoubiquitination might break apart the complex into active monomers which then exhibit distinct DNA substrate specificities [52]. According to an evolving model, FANCI and FANCD2 may also function separately at different stages of the repair process. Future research is needed to clarify the function and precise regulation of ID complex formation.

2.6. Negative regulation of FA pathway by USP1

The deubiquitinating enzyme, USP1 is an important regulator of the FA pathway because it deubiquitinates FANCD2 [53]. USP1 depletion increases FANCD2 monoubiquitination both at the steady-state as well as after DNA damage. Unexpectedly, despite there being an increase in Ub-FANCD2 levels, USP1 depletion results in increased crosslinker sensitivity, impaired HR repair, chromosomal aberrations and constitutively chromatin-bound FANCD2. This has led to the model that USP1 is required for recycling and releasing Ub-FANCD2 from chromatin [54, 55]. USP1 exists as a stoichiometric complex with the activator subunit UAF-1 (USP1-associated factor) [56]. The UAF1 contains a tandem repeat of SUMO-like domains at its C-terminus and one of the domains (SLD2) binds directly to the SUMO-like domain interacting motif of FANCI. Thus, UAF1/USP1 proteins get targeted to the FANCI/FANCD2 heterodimer [57]. Both *Usp1* and *Uaf1* deficiency in mice caused an increase in chromosomal aberrations,

crosslinker sensitization, defective HR and impaired FANCD2 focus assembly. These results indicate that FANCD2 monoubiquitination levels have to be tightly regulated for the proper functioning of the FA pathway [58, 59].

2.7. FANCD2 chromatin localization and nuclear focus formation after DNA damage

The monoubiquitination of FANCD2 is necessary but not sufficient for FANCD2 chromatin retention and nuclear focus formation. This is because monoubiquitination of FANCD2 can be uncoupled from focus formation upon the depletion of certain genes, suggesting the existence of additional layers of regulation in the FA pathway.

For example, the depletion of BRCA1 does not impair FANCD2 monoubiquitination, but only FANCD2 nuclear focus formation [60]. Interestingly, depletion of KU70 overrode the requirement for BRCA1 in FANCD2 recruitment to DNA damage foci, indicating that NHEJ proteins may negatively regulate FANCD2 focus formation. FANCD2 chromatin retention and focus formation are also defective in the absence of XPF-ERCC1 suggesting that a specific DNA structure created by the XPF-ERCC1 mediated-incision might stabilize the chromatin association of Ub-FANCD2 [61]. USP1 and UAF-1 depletion also give rise to impaired FANCD2 focus formation, but increase Ub-FANCD2. Phosphorylated H2AX is also essential for FANCD2 focus formation [62]. Recently, the RUNX family of transcription factors were demonstrated to control FANCD2 chromatin localization and focus formation, but not FANCD2 monoubiquitination. In a non-transcriptional but DNA damage-dependent manner, RUNX proteins interact with the FANCI/FANCD2 heterodimer. The disruption of RUNX proteins in mice gave rise to FA phenotypes such as BMF, MDS and crosslinker sensitivity [63]. Moreover, in at least two FA patients genomic deletions in the region bearing RUNX1 have been identified [64, 65]. In another example, FANCD2 chromatin retention and focus formation are regulated by FANCI, independent of FANCD2 monoubiquitination [66]. It is possible that multiple proteins co-operatively regulate the FANCD2 focus formation step, because once Ub-FANCD2 lodges itself at the site of DNA damage, it 'licenses' the incision step by orchestrating the recruitment of DNA cleaving nucleases.

2.8. Unhooking of the crosslink

The incision of the parent DNA strand on either end of the crosslink is referred as the 'unhooking step' of ICL repair. Several structure-specific endonucleases have been implicated in the incision process such as the FAN1 nuclease, SLX4-SLX1 heterodimer, XPF-ERCC1 complex, MUS81-EME1 heterodimer and the SNM1 nuclease.

The 'unhooking' step of ICL repair is dependent on FANCD2 monoubiquitination and focus formation [67] because the ubiquitin domain of FANCD2 can recruit both FAN1 and SLX4. In a ShRNA (short hairpin RNA) screen for crosslinker resistance, FAN1 was identified as a DNA repair nuclease that undergoes recruitment through its UBZ domain (ubiquitin binding domain) by binding to Ub-FANCD2. FAN1 has both 5'-3' exonuclease activity and 5' flap endonuclease activities. Depletion of FAN1 causes crosslinker sensitivity and defective ICL repair [68-70].

In addition to FAN1 nuclease, ICL processing also involves the SLX4 protein, which complexes with several proteins such as the MUS81-EME1, XPF-ERCC1 heterodimers and the SLX1 nuclease. SLX4 is mutated in FA patients belonging to the complementation group FANCP and results in crosslinker sensitivity and chromosomal aberrations [71-73]. Similarly, ERCC4, the gene that encodes for XPF, undergoes biallelic mutations in FA patients, resulting in XPF being designated as FANCQ [74].

The SLX4 complex cleaves 3'flap, 5'flap and replication fork structures and promotes symmetrical cleavage of static and migrating Holliday junctions, identifying it as a Holliday junction (HJ) resolvase [75]. The ubiquitin-binding zinc finger domain (UBZ) of SLX4 mediates its interaction with Ub-FANCD2 leading to its recruitment to DNA damage sites [76]. In more detailed structure-function analysis, it has been found that the N-terminus of SLX4 protein that only binds XPF-ERCC1 is sufficient to confer DNA crosslinker resistance [77, 78]. SLX4 enhances XPF-ERCC1 nuclease activity *in vitro* by 100-fold and stimulates dual incisions around a DNA crosslink embedded within a synthetic replication fork [79].

According to another line of evidence, XPF-ERCC1 might be sufficient to make the dual incision during ICL repair. In elegant *in vitro* biochemical studies, the XPF-ERCC1 complex makes an incision 5' to a psoralen lesion on a Y-shaped DNA in a damage-dependent manner. Subsequent to the first incision, it creates a second incision specific to the 3'-end side of the ICL. The ICL-specific 5' and 3' incisions result in the separation of the two crosslinked DNA strands resulting in 'unhooking' [80]. Another nuclease that collaborates with XPF-ERCC1 is the mammalian homolog of yeast Pso2 exonuclease, the human SNM1A. hSNM1 exhibits a 5'-3' exonuclease activity and initiates ICL repair by creating a favourable substrate for TLS through its nucleolytic action [81]. In summary, multiple nucleases engender the incisions required for ICL repair to proceed, although the relative contribution of these nucleases and the order of their recruitment are not fully clear.

2.9. Downstream of FANCD2 monoubiquitination- FANCD1 (BRCA2), FANCI, FANCO and FANCN

The Fanconi proteins FANCD1 (BRCA2), FANCI (BRIP1), FANCO and FANCN (PALB2) are loosely referred to 'downstream proteins' in the FA pathway because they act downstream to the FANCD2 monoubiquitination step. Mutations in these proteins give rise to more severe phenotypes in FA patients especially with regards to cancer onset.

FANCD1: The biallelic inactivation of FANCD1 or BRCA2 in Fanconi anaemia patient families created tremendous excitement at the time of the discovery, because it linked FA with a gene closely associated with hereditary cancer susceptibility [82]. Also, it strengthened the idea that the FA and BRCA pathway are intimately linked for the successful repair of ICL damage.

BRCA2 is a central protein of HR repair of DNA damage. In response to double strand breaks, BRCA2 mediates the delivery of RAD51 to ssDNA and facilitates the displacement of RPA from ssDNA. RAD51 is a protein that forms a nucleoprotein filament on ssDNA and invades DNA duplex to search for sequence homology. It is suggested that monoubiquitination of

FANCD2 is needed for BRCA2 loading to DNA damage foci, indicating a functional coupling between FANCD2 monoubiquitination and HR [83].

FANCF is also called as BRCA1-associated helicase or BRIP1. FANCF-depleted cells show crosslinker sensitivity and chromosomal instability after mitomycin C treatment [84, 85]. Using a chromatin-IP (immunoprecipitation) based method, recruitment of FANCF and FANCD1 to DNA crosslinked sites was found to be FA core complex-independent, but DNA replication-dependent [86].

FANCF has both DNA-dependent ATPase and helicase activities. The helicase activity of FANCF is a target for mutational inactivation in patients and it depends on the ATPase activity [87]. FANCF preferentially binds and unwinds forked duplex substrates and 5' flap substrates which arise during normal replication and repair. Although FANCF was isolated as a BRCA1-binding protein, the repair function of FANCF is independent of its BRCA1 binding because a FANCF mutant deficient for BRCA1 binding can still rescue the crosslinker sensitivity of FANCF-deficient chicken DT-40 cells [88]. On the other hand, genetic studies have revealed that instead of BRCA1-binding, FANCL-MLH1 binding is essential for FANCF to be able to correct crosslinker sensitivity of FANCF-null cells [89].

RAD51C (FANCD2) is essential for HR-mediated repair of lesions associated with replication and controls the intra-S checkpoint through CHK2 activation [90]. RAD51C mutation resulted in a Fanconi-anemia like disorder in a family with several congenital abnormalities characteristic of FA [91]. RAD51C is a part of a complex that also contains PALB2 and BRCA2. FA and cancer-associated RAD51C mutants that show reduced complex formation with PALB2 also have a reduced capacity for HR repair [92].

Partner and localizer of BRCA2 or PALB2 mutations were detected in the Fanconi complementation group N patients. FANCD1-deficient cells are sensitive to mitomycin C, are defective for BRCA2 loading and RAD51 focus formation and have reduced HR activity [93, 94]. PALB2 was originally identified as a BRCA2-interacting protein and it physically links BRCA1 and BRCA2 to form the so-called BRCA-complex [95, 96]. PALB2 focus formation after DNA damage was itself dependent on BRCA1. PALB2 is important for BRCA2 localization to sites of DNA damage and in supporting BRCA2 function during HR. Clinically relevant point mutations that either disrupt PALB2-BRCA1 or PALB2-BRCA2 binding fail to support HR [97]. Thus, an intact BRCA1-PALB2-BRCA2 pathway is essential for HR and in the suppression of FA phenotypes.

2.10. Translesion synthesis: after unhooking of the crosslink

Translesion synthesis (TLS) is an inherently error-prone pathway that promotes DNA repair by allowing the bypass of a stalled-replication intermediate [98]. Although this process can increase genomic instability in the form of point mutations, the TLS step is required during ICL to generate the intact template for HR. Consistently, genomic analysis of FA patient samples revealed a 'hypomutability' phenotype with respect to point mutations [99].

TLS is achieved because the canonical replicative polymerase is replaced by the translesion polymerase that can accommodate DNA lesions into a larger active site. Several classes

of human translesion polymerases like Rev1, Pol zeta, Pol eta, Pol kappa, Pol iota, and Pol nu participate in replication-dependent ICL repair and extent of bypass depends upon the structure of the crosslinking agent as well as the extent of nucleolytic processing of the crosslink [100].

Of the various translesion polymerases, Rev1 and the translesion polymerase eta form foci at sites of damage in a PCNA-dependent manner. After DNA damage, PCNA is monoubiquitinated in a RAD6/RAD18-dependent manner at lysine 164. PCNA is a sliding clamp that carries the replication polymerase delta along DNA during replication. When PCNA undergoes monoubiquitination, it switches the canonical DNA polymerase into the translesion polymerase eta, which allows for lesion bypass due to a larger active site. Monoubiquitinated PCNA also stabilises the recruitment of another translesion polymerase, Rev1. Rev1 is a deoxycytosine monophosphate (dCMP) transferase that can insert a cytosine opposite the unhooked ICL. Rev1 recruitment and focus formation is also promoted in a PCNA-independent manner because the FAAP20 subunit of FA core complex binds to ubiquitinated Rev1 through its Zinc finger 4 domain and stabilizes Rev1 nuclear foci [101]. Intriguingly, PCNA monoubiquitination has TLS-independent role in promoting the monoubiquitination of FANCI and FANCD2 in a FANCL-dependent manner [102]. These findings indicate multiple levels of crosstalk between the FA and TLS pathways.

2.11. ICL repair: HR (HR)

The by-product of the 'unhooking' step is the generation of a broken strand of DNA that is repaired by the FA pathway using HR. HR is initiated by a DNA end-resection reaction that creates the 3' overhangs.

During ICL repair, the MRN complex and CtIP participate in the end resection reaction. ATR phosphorylates the MRN complex which is required for the resection of the double strand created after the excision of the ICL to create 3' overhangs. Recently, CtIP has been found to undergo recruitment to DNA repair sites in a FANCD2 monoubiquitination-dependent manner to start the end resection reaction. The interaction between CtIP and Ub-FANCD2 is required for the formation of mitomycin C-induced CtIP foci and RPA phosphorylation. It is proposed that Ub-FANCD2 channels ICL repair into the error-free HR pathway by tethering CtIP to damaged chromatin. Thus, CtIP prevents illegitimate recombination during ICL repair [103, 104]. In another study, FANCD2 binding to CtIP has been observed to promote replication fork-restart [105].

After end resection, RAD51 plays an important role in HR repair. Although RAD51 functions downstream of FANCD2 monoubiquitination, RAD51 recruitment to stalled -replication forks happens independently of FANCI/FANCD2 and before double strand break (DSB) formation. The depletion of RAD51 from *Xenopus* egg extracts completely disrupted ICL repair by HR [4].

More recently, the role of FA proteins in HR has been firmly established using the TR-GFP assay. In this assay, ICL formation is achieved by conjugating a triplex-forming oligonucleotide to the crosslinking agent psoralen. Using this system, a profound defect in ICL-induced HR

was observed in FA patient cells, but only upon reporter replication [106], providing evidence that FA proteins are essential for replication-coupled ICL repair by HR.

According to another line of thinking, one of the principal functions of FANCD2 is to channel DSBs away from error-prone NHEJ into error-free HR. Accordingly, the concurrent disruption of FANCC and KU70 suppressed crosslinker sensitivity, reduced chromosomal breaks and reversed defective HR in chicken DT40 cells [107]. Similarly, the DNA repair defects of *C.elegans* FANCD2 mutants can be rescued by simultaneously eliminating the NHEJ pathway, leading to the conclusion that FA-defective phenotype may be consequence of promiscuous end-joining reactions catalysed by NHEJ [108]. However, similar results were not obtained in mice, where the depletion of KU or 53BP1, another NHEJ factor, exacerbated genomic instability in cells lacking FANCD2 [60]. Regardless of whether NHEJ inhibition is the sole function of the FANCD2 monoubiquitination or not, at the least, it can be concluded that channelling DSBs away from toxic NHEJ into error-free HR is one of the important downstream outputs of an activated FA pathway.

2.12. Endogenous sources of DNA interstrand crosslinks

The DNA repair defects associated with the FA pathway have been studied *in vitro* mostly after the exogenous addition of crosslinking agents like cisplatin or mitomycin C. However, FA patients show their disease manifestations without evidence for prior exposure to exogenous crosslinkers. This indicates that human cells are inadvertently exposed to endogenous genotoxic agents and the FA pathway preserves the genomic integrity of cells in the presence of such stresses.

In recent studies, reactive aldehydes have emerged as one of the endogenous agents capable of generating lesions that have to be repaired by the FA pathway. One such example is acetaldehyde, an intermediate by-product of alcohol metabolism. Acetaldehyde is enzymatically catabolised into acetate by the acetaldehyde dehydrogenase, ALDH2. In the absence of ALDH2, acetaldehyde accumulates and binds DNA to form N2-ethylidene-dG adducts. In *Aldh2*-knockout mice that have been exposed to 8% ethanol for 14 months, increased genotoxic stress in the form of N(2)-ethylidene-dG DNA adduct accumulation is evident in the oesophagus, tongue and submandibular gland [109-111]. Furthermore, epidemiological studies have demonstrated a strong correlation between long-term drinking and a predisposition for oral and esophageal cancers in people bearing the ALDH2*2 polymorphism (a dominant negative isoform of ALDH2).

To understand whether the FA pathway protects cells against the genotoxic effects of aldehydes, mice double-deficient for ALDH2 and FANCD2 were generated. *Aldh2* and *Fancd2* double knock-out mice exhibited lethality at the embryonic stage. However, when these embryos were transferred into ALDH2-catabolism efficient mothers (*Aldh2*^{+/-}), the mice were born to term, but had developmental defects and leukemic predisposition. Aged-double mutant *Aldh2*^{-/-}*Fancd2*^{-/-} mice that did not develop leukemia spontaneously developed aplastic anemia, another characteristic feature of human FA patients, together with a drastic 600-fold depletion in haematopoietic stem cell pools [112]. Similar results were obtained in

chicken DT-40 cells, where ADH5 (formaldehyde-catabolising enzyme) and FA pathway factors exhibited a synthetic lethal genetic interaction [113]. The developmental phenotypes and embryonic lethality associated with *Aldh2*^{-/-}*Fancd2*^{-/-} embryos could be rescued by transferring such embryos into aldehyde catabolism-efficient wild-type mothers. This suggested that maternal aldehydes emanating from ALDH2-deficient mothers can be transferred via the placenta into the growing foetus resulting in embryonic lethality [114]. When such 'rescued' *Aldh2*^{-/-}*Fancd2*^{-/-} neonates are analysed after birth, they still had severely depleted hematopoietic stem cell pools. This indicated that both fetal and maternal aldehyde detoxification systems are important to counteract the genotoxic effects of aldehydes in the growing embryo. Together, the above studies provided a glimpse on how the repair of aldehyde-mediated damage of the haematopoietic stem cell pool might be one of the underlying functions the FA pathway and can explain the haematopoietic defects of human FA patients.

3. NON-ICL repair function of the FA pathway

It has recently emerged that the FA pathway can also function in an ICL-repair independent manner for the maintenance of genomic integrity. In this section, we will discuss how the FA proteins participate in alternative genome-maintenance pathways.

One of the main ICL repair-independent functions of FANCD2 is that it co-operates with BRCA2 and RAD51 to protect stalled-replication forks from nucleolytic degradation [115]. FANCD2 also co-ordinates the re-start of stalled-replication forks in concert with the BLM helicase and recruits the FAN1 nuclease to promote the re-start of forks [116, 117]. Consistently, FA proteins FANCI and FANCD2 localize to stalled-replication forks in mass spectrometric studies [118]. Apart from FANCD2, other FA proteins FANCM, FAAP24, MHF1 and MHF2 were also found to play an important role in stabilizing stalled replication forks. The ATPase-dependent FANCM translocase activity is needed for replication fork stability. Cells expressing translocase-deficient FANCM showed altered global replication dynamics and stalled replication forks that result in the formation of spontaneous DSBs and 53BP1-marked nuclear bodies called as 53BP1-OPT domains in the G1 phase of cell cycle [119]. Similarly, loss of *Fancc* exacerbated genomic instability by impairing fork progression during DNA replication in a tumor-prone mouse model that had ~60% loss of dormant origins [120].

FANCI and FANCD2 also bind indirectly to minichromosome maintenance (MCM) proteins that are present in nascent DNA after replication arrest. FANCD2 was found essential for cells to restrain DNA synthesis in the presence of reduced pool of nucleotides. In an ATR-dependent but monoubiquitination-independent way, FANCD2 is required for general replisome surveillance mechanisms [121].

FA proteins may also promote genomic integrity in a transcription-dependent manner. For instance, *Fancd2*-deficient mice are susceptible to squamous cell carcinomas of the skin in response to Ras oncogene induction. Ub-FANCD2 activates the transcription of a tumor suppressor *TAp63* to prevent skin carcinogenesis [122]. FANCD2 also interacts with NFκB in

Figure 3. The Fanconi anemia pathway maintains genomic integrity in ICL-repair dependent and independent manner

the TNF-alpha promoter region. Defective FANCD2 causes the activation of TNF-alpha and the production of inflammatory cytokines [123]. Inflammatory cytokines, in turn, are an important source of reactive oxygen species to increase the DNA damage exposure of FA-defective cells.

The FA pathway is also required for maintaining the genomic integrity of B cells during class switch recombination (CSR). FANCA is required for the induction of transition mutations at A/T residues during somatic hypermutation and to prevent short-range recombination downstream of DSB formation during CSR [124].

The FA pathway co-operates with BLM to maintain genomic integrity during mitotic progression. FA pathway-dependent BLM targeting to non-centromeric abnormal structures induced by replication stress has an important role in mitotic progression because it prevents micronucleation and reduces aneuploidy in daughter cells [125]. FA-pathway deficient cells also express a higher number of UBFs (ultra-fine bridges) as compared to wild-type cells. This was attributed to the higher rate of cytokinesis failure in FA-impaired cells resulting in binucleated cells [126] (Figure. 3).

4. The Fanconi anemia pathway as an anti-cancer barrier

In the last section of this chapter, we will examine how the FA proteins suppress tumorigenesis. *There are three lines of evidence linking FA pathway disruption and human cancer. Firstly, FA patients have a heightened risk for developing leukemias and solid tumors in their life time as compared to the general population. Secondly, mouse models deficient for FA genes spontaneously develop tumors. Lastly, FA gene mutations have been uncovered from cases of human sporadic cancers, suggesting that they could be drivers of genomic instability in human cancers.*

4.1. Cancer Incidence in FA patients

Due to variability in clinical manifestations between FA patients, phenotypes such as BMF, haematological malignancies and solid tumors were used to subdivide patients. In general, anywhere between 20%-80% of FA patients experience BMF. About ~30% of FA patients get cancers, although this number can vary depending on the patient's risk for getting BMF. For example, the high-BMF risk category have a lower chance of getting cancers because they may not live long enough, whereas the patients in the lowest BMF risk group were likely to live long enough and get leukemias or solid tumors [127]. The risk for getting all types of cancers including leukemia and solid tumors is 50-fold higher in the FA population as compared to the non-FA population [128]. In a literature survey published in 2003, cancer incidence was measured in 1300 FA patients for the years in between 1927-2001 [129]. While the median age for cancer development was ~68 years in the normal population, it significantly dropped to a median age of only 16 years for the FA population. Of the patients who developed tumors, about 60% had tumors of haematological origin and 40% were solid tumors. The risk for getting leukemia in the FA population is 800-fold higher than the general population [130, 131]. Haematological cancers, in particular, acute myeloid leukemia and myelodysplastic syndrome accounted for ~50% of cancers in FA patients by age 40. FA-related leukemias were myeloid in 94% of the cases and only 6% of the leukemias were lymphoid in nature. This pattern strongly differed from spontaneous leukemias, where ~84% were lymphoid in nature.

Amongst the solid tumors, ~50% were squamous cell carcinomas of the head and neck, anogenital region, skin, vulvar region, oesophagus and cervix and 10% were liver tumors. When compared to the general population, the risk is for getting all solid tumors is 48-fold higher in the FA population and in the range of 100-1000 fold higher for head and neck cancers and for cancers of the esophagus, liver, vulva, and cervix [130]. Solid tumors had a slower incidence at younger age, but the probability of getting a solid tumor dramatically increased to 76% by age 45, suggesting that older FA patients had a significantly higher risk for developing solid tumors.

It is noteworthy that there is considerable variability between FA patients with respect to the spectrum of cancers manifested and the age of cancer-onset. In general, mutations in FA core proteins result in a milder cancer phenotype as compared to mutations in downstream genes. For example, FA patients belonging to the FANCD1 (BRCA2) subgroup have a much higher risk for an earlier onset of malignancies. The cumulative probability of getting any malignancy such as leukemia or solid tumors in a FANCD1 subtype patient was ~97% by age 5.2 years, indicating that amongst FA patients, FANCD1 subtype was the most severe with respect to their risk for developing malignancies [132, 133]. Similarly, patients of the subtype FANCD1, FANCO and FANCI show greater predisposition for developing breast cancers, whereas patients of the subtype FANCO are likely to get ovarian cancers. In summary, cancer spectrum and the age of cancer-onset are reflective of the distinct roles played by the FA proteins during ICL repair.

4.2. FA pathway disruption predisposes knockout-mice to cancers

Immediately following the discoveries of mutations responsible for human FA, a number of groups generated mice defective for FA proteins. The first mouse models to be generated were the *Fancc*^{-/-} mice and *Fanca*^{-/-} mice (exons 4-7 deletion). These mice had normal viability and no developmental defects, but impaired fertility. *Fancc*^{-/-} and *Fanca*^{-/-} cells had characteristic crosslinker sensitivity and exhibited several-fold higher accumulation of chromosomal aberrations after treatment with crosslinking agents [134, 135]. Another mouse model for *Fanca* bore deletions in exons 1-6 and these mice showed more severe phenotypes like prenatal growth retardation, craniofacial abnormalities, and crosslinker sensitivity which were all typical features of human FA patients [136]. *Fancg*^{-/-} mice also showed hypogonadism, impaired fertility and cells isolated from these mice had an accumulation of spontaneous chromosomal aberrations, increased sensitivity to mitomycin C [137, 138]. Together, the characteristics of *Fancc*^{-/-}, *Fanca*^{-/-} and *Fancg*^{-/-} mice strongly resembled each other, supporting the premise that they function in a common pathway. Yet, phenotypes evident in human FA patients such as typical haematological manifestations and increased risk for spontaneous cancers could not be recapitulated in these mouse models. It was also hypothesised that the benign environment in typical mouse facilities did not provide sufficient exogenous stress to precipitate FA phenotypes. Hence, *Facc*^{-/-} knockout mice were challenged with clastogens such as mitomycin C. Upon crosslinker exposure, *Facc*^{-/-} mice showed progressive pancytopenia and died within a few days [139]. Interestingly, double-deficient mice defective in *Fancc* and *Fancg*, in C57BL/6J background started displaying haematological manifestations seen in FA patients, such as BMF, acute myeloid leukemia (AML), MDS, and complex chromosomal rearrangements that were not seen in the single KO mice. Hence, this mouse model was considered a close mimic of human FA, especially with respect to onset of haematological malignancies [140].

Fancd2^{-/-} mice are viable, but show prenatal and post-natal growth retardation. The severity of the phenotypes in *Fancd2*^{-/-} mice is mouse strain-dependent and mice generated in the C57BL/6J background had more severe phenotypes than those in 129S4 background. *Fancd2*^{-/-} mice shared phenotypes common with *Fanca*^{-/-}, *Fancc*^{-/-} and *Fancg*^{-/-} mice such as impaired fertility, increased chromosomal aberrations and sensitivity to MMC. In addition, *Fancd2*^{-/-} mice also exhibited unique features such as microphthalmia and perinatal lethality. *Fancd2*^{-/-} mice were particularly tumor-prone, and showed epithelial cancers in several tissues that eventually caused their mortality. The tumors found in *Fancd2*^{-/-} mice included ovarian cancers, hepatic adenoma and adenocarcinoma, gastric cancers, mammary B cell lymphoma, lung adenocarcinoma and bronchoalveolar carcinoma [141]. Tumor formation was further accelerated when *Fancd2*^{-/-} mice were crossed with *p53*^{+/-} mice. The tumor spectrum found in the double mutant mice included mammary and lung adenocarcinomas, cancers rarely seen in the *p53*^{+/-} heterozygotes [142]. More recently, mice double-deficient for *Fancd2* and *Aldh2* were generated. Due to aldehyde-mediated genotoxicity, such mice showed leukemic predisposition and BMF [143]. The above studies reiterate that FA phenotypes are strongly influenced by the type and extent of genotoxic stress exposure. Only when cells accumulate

unrepaired crosslinks beyond a certain threshold, FA phenotypes such as developmental abnormalities, BMF, haematological malignancies and solid tumors are manifested.

Another example, where the absence of FA core proteins results in increased cancer incidence are *Fancf*^{-/-} mice and *Fancm*^{-/-} mice. *Fancf*^{-/-} mice showed increased incidence of ovarian cancers whereas *Fancm*^{-/-} mice showed tumors such as lymphomas, histiocytic sarcoma, hepatoma and lung carcinomas [144, 145].

Apart from core FA proteins, mouse models were also generated for the downstream proteins involved in the unhooking step or in HR. Mice deficient for SLX4 recapitulated several key features of FA. These mice were born at submendelian ratios, had fertility defects and were prone to blood cytopenias. *Slx4*^{-/-} cells show increased chromosomal aberrations and cross-linker sensitivity [72]. *Slx4*-deficient mice also developed epithelial cancers and died by 100 weeks with haematological cancers and solid tumors such as squamous cell carcinomas, hepatocellular carcinoma and ovarian tumors. Thus, SLX4 deficiency closely mimicked the clinical features of human FA.

According to human genetic data, the heterozygosity of HR proteins cause increased susceptibility to breast, ovarian and other cancers whereas biallelic mutations in HR genes cause FA. A homozygous deletion of HR genes, however, results in an embryonic lethal phenotype. Consistently, mice bearing homozygous deletion of repair proteins involved in HR such as BRCA2, PALB2 and Rad51C show embryonic lethality with gross chromosomal aberrations [146, 147]. But, when hypomorphic strains were derived for these mice, an FA phenotype could be observed. For example, mouse expressing a hypomorphic *Palb2* allele showed reduced fertility, MMC hypersensitivity and chromosomal breakage when treated with mitomycin C [148]. Similarly, thymic lymphomas were observed in mice expressing a truncated form of BRCA2 [149]. Homozygous deletion of exon 27 of *Brca2* prevents its interaction with RAD51. Hence, mice carrying homozygous deletion of exon 27 of *Brca2* were generated and several phenotypes in these mice recapitulated phenotypes observed in human FA patients of the complementation group FANCD1. *Brca2*^{Δ27/Δ27} mice showed haematological defects such as compromised progenitor cell function, reduced hematopoietic stem cell self renewal, spontaneous accumulation of chromosomal aberrations and sensitivity to crosslinking agents. In addition, *Brca2*^{Δ27/Δ27} mice were more prone to epithelial tumors such as squamous cell carcinomas of gastric origin and mammary gland, endometrial cancers, sarcomas and lung cancers [150, 151].

4.3. Fanconi anemia pathway in human sporadic cancer

The discovery that bi-allelic mutations in BRCA2 manifests as FA was a major conceptual advance because it linked FA with a gene responsible for familial cancers. FA phenotypes such as cancer predisposition could now be directly linked to HR and DNA repair [82, 152].

However, only about 25% of human hereditary cases of breast cancer are owing to BRCA1 or BRCA2 mutations. Therefore, it was hypothesized that mutations in BRCA1-related FA pathway genes such as FANCI, FANCD1 and FANCD2 could be responsible for BRCA1/BRCA2-negative breast and ovarian human cancers. Amongst these, there is strong evidence that germ-

line mutations in BRIP1 increase the susceptibility to familial ovarian cancer [153]. Similarly, germ-line mutations in FANCO (RAD51C) increase susceptibility to ovarian cancer and breast cancer [154-157]. PALB2 (FANCN) mutations have been uncovered in 1-4% of inherited breast cancer patients [158, 159]. Polymorphic FANCA mutations were also detected in high-risk non-BRCA1/BRCA2 breast cancer patients in a French Canadian population [160]. FANCM has also emerged as a breast cancer susceptibility gene in a Finish population and FANCM mutations confer strong predisposition for triple-negative breast cancers [161]. PALB2, FANCC and FANCG mutations have also been associated with increased risk for pancreatic cancer [162-164]. In summary, a small but significant proportion of familial cancers are driven by mutational inactivation of FA genes.

There is also accumulating evidence that genes of the FA pathway may undergo inactivation by epigenetic silencing in some sporadic human cancers. FANCF promoter methylation and inactivation was observed in lung and oral cancers and promoter methylation correlated with smoking and alcohol use [165]. FANCF promoter methylation and inactivation was also observed in ovarian cancer patients [166]. Epigenetic inactivation of FANCA was observed in non-small cell lung cancer due to microRNA miR-503 dependent de-regulation [167]. An early-stage inactivation of FANCC due to promoter methylation was observed in dysplastic lesions of the head and neck [168]. FANCA and BRCA2 promoters were recurrently methylated in laryngeal squamous cell carcinoma [169]. FANCC and FANCL promoters were hypermethylated in sporadic acute leukemia [170], PALB2 promoter was methylated in sporadic breast and ovarian cancer [171], FANCF promoter was methylated in sporadic breast cancer [172] and ovarian cancer [173, 174] cervical cancer [175] and in AML [176]. In an unknown manner, FANCD2 expression was reduced in human uveal melanoma and influenced spontaneous sister chromatid exchange and RAD51 focus formation [177]. Cancer-associated alterations in the form of deletions were recovered for FANCC in breast cancers [178]. Put together, the inactivation of FA genes might be a common feature in several sporadic cancers.

Lastly, cancer genomics has enabled the analysis of the cancer genome in a high-throughput manner. When cancer genomes are queried for mutational inactivation of the 16 FA genes (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FANCD1, FANCN, FANCO, FANCP, FANCQ), nearly 25-30% of solid tumors show a mutational inactivation of one of genes (<http://www.cbioportal.org/public-portal>, [179, 180] (Figure. 4).

Given that an intact FA pathway is required for the successful repair of ICLs, the inactivation of any of the FA genes can potentially lead to genomic instability during cancer progression. At the same time, genomic instability due to disrupted FA pathway can be exploited for therapy because such cancers by targeted by chemotherapeutics known to cause DNA interstrand crosslinking like Cisplatin. Further functional characterisation of cancer-associated FA mutations is required to provide clearer knowledge on the role of the FA pathway in sporadic human cancer.

Figure 4. Genomic characterization of FA proteins in human cancer

5. Conclusion

Even though FA was described several decades ago, a thorough knowledge on the functional aspects this pathway has emerged only in the last 15 years. Mechanistic studies have revealed that FA proteins orchestrate the complex process of ICL repair. Unrepaired crosslinks are a major source of genomic instability and responsible for several FA patient phenotypes. But, according to recent studies, FA proteins may also fulfil DNA repair-independent roles to maintain genomic integrity. As even more proteins are being ascertained as accessory factors of this pathway, the study of FA is becoming complex, but exciting.

The most serious complication for FA patients at a young age is aplastic anemia, but, this haematological complication can be mostly treated by stem cell transplantation. An even greater concern for FA patients is their risk for getting leukemias and solid tumors at an older age. The observation that reactive aldehydes are a major source of ICLs has given hope to FA patients that reducing aldehydes levels can perhaps reduce cancer incidence. If environmental or metabolic sources of ICL agents are discovered, then such risk factors can be mitigated to reduce cancer burden in FA patients.

We now know that an intact FA pathway and enzymatic detoxification of aldehydes act together to provide a double-tier protection against crosslinking lesions. Given that ~500 million people world-wide have polymorphisms that make their aldehyde-detoxification pathways inefficient, studying the FA pathway is likely to gain more importance from a human health perspective. Importantly, several known human carcinogens like tobacco smoke, nitrosamines from diet and alcohol can result in potentially genotoxic interstrand crosslinking lesions within cells.

Indeed, the likelihood for getting sporadic human cancer has increased at an alarming rate over the past few decades. Given that the FA pathway lies at the interface of genome maintenance and human cancer, further studies on this pathway can lead to novel strategies for cancer prevention.

Abbreviations

Acute myeloid leukemia (AML)

Ataxia telangiectasia-mutated related (ATR)

Bone marrow failure (BMF)

Double strand break (DSB)

Double-stranded DNA (dsDNA)

Fanconi Anemia (FA)

Homologous recombination (HR)

Interstrand crosslink (ICL)

Monoubiquitinated FANCD2 (Ub-FANCD2)

Myelodysplastic syndrome (MDS)

Non-homologous end joining (NHEJ)

Single-stranded DNA (ssDNA)

Translesion synthesis (TLS)

Acknowledgements

This research is supported by the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative.

Author details

Vaidehi Krishnan*, Lavina Sierra Tay and Yoshiaki Ito

*Address all correspondence to: csivk@nus.edu.sg

Cancer Biology Program, Cancer Science Institute of Singapore, National University of Singapore, Singapore

References

- [1] Magana-Schwencke N, Henriques J, Chanet R, Moustacchi E. The fate of 8-methoxypsoralen photoinduced crosslinks in nuclear and mitochondrial yeast DNA: comparison of wild-type and repair-deficient strains. *Proceedings of the National Academy of Sciences*. 1982;79(6):1722-6.
- [2] Räschle M, Knipscheer P, Enoiu M, Angelov T, Sun J, Griffith JD, et al. Mechanism of replication-coupled DNA interstrand crosslink repair. *Cell*. 2008;134(6):969-80.
- [3] Long DT, Joukov V, Budzowska M, Walter JC. BRCA1 Promotes Unloading of the CMG Helicase from a Stalled DNA Replication Fork. *Molecular cell*. 2014.
- [4] Long DT, Räschle M, Joukov V, Walter JC. Mechanism of RAD51-dependent DNA interstrand cross-link repair. *Science*. 2011;333(6038):84-7.
- [5] Knipscheer P, Räschle M, Smogorzewska A, Enoiu M, Schärer OD, Elledge SJ, et al. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. *Science*. 2009;326(5960):1698-701.
- [6] Walden H, Deans AJ. The Fanconi Anemia DNA Repair Pathway: Structural and Functional Insights into a Complex Disorder. *Annual review of biophysics*. 2014(0).
- [7] Ciccica A, Ling C, Coulthard R, Yan Z, Xue Y, Meetei AR, et al. Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM. *Molecular cell*. 2007;25(3):331-43.
- [8] Meetei AR, Medhurst AL, Ling C, Xue Y, Singh TR, Bier P, et al. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. *Nature genetics*. 2005;37(9):958-63.
- [9] Gari K, Décaillot C, Stasiak AZ, Stasiak A, Constantinou A. The Fanconi anemia protein FANCM can promote branch migration of Holliday junctions and replication forks. *Molecular cell*. 2008;29(1):141-8.
- [10] Xue Y, Li Y, Guo R, Ling C, Wang W. FANCM of the Fanconi anemia core complex is required for both monoubiquitination and DNA repair. *Human molecular genetics*. 2008;17(11):1641-52.
- [11] Huang M, Kim JM, Shiotani B, Yang K, Zou L, D'Andrea AD. The FANCM/FAAP24 complex is required for the DNA interstrand crosslink-induced checkpoint response. *Molecular cell*. 2010;39(2):259-68.
- [12] Collis SJ, Ciccica A, Deans AJ, Hořejší Z, Martin JS, Maslen SL, et al. FANCM and FAAP24 function in ATR-mediated checkpoint signaling independently of the Fanconi anemia core complex. *Molecular cell*. 2008;32(3):313-24.
- [13] Schwab RA, Blackford AN, Niedzwiedz W. ATR activation and replication fork restart are defective in FANCM-deficient cells. *The EMBO journal*. 2010;29(4):806-18.

- [14] Wang Y, Leung JW, Jiang Y, Lowery MG, Do H, Vasquez KM, et al. FANCM and FAAP24 maintain genome stability via cooperative as well as unique functions. *Molecular cell*. 2013;49(5):997-1009.
- [15] Singh TR, Saro D, Ali AM, Zheng X-F, Du C-h, Killen MW, et al. MHF1-MHF2, a histone-fold-containing protein complex, participates in the Fanconi anemia pathway via FANCM. *Molecular cell*. 2010;37(6):879-86.
- [16] Yan Z, Delannoy M, Ling C, Daee D, Osman F, Muniandy PA, et al. A histone-fold complex and FANCM form a conserved DNA-remodeling complex to maintain genome stability. *Molecular cell*. 2010;37(6):865-78.
- [17] Zhao Q, Saro D, Sachpatzidis A, Singh TR, Schlingman D, Zheng X-F, et al. The MHF complex senses branched DNA by binding a pair of crossover DNA duplexes. *Nature communications*. 2014;5.
- [18] Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. *Molecular cell*. 2010;40(2):179-204.
- [19] Pichierri P, Rosselli F. The DNA crosslink-induced S-phase checkpoint depends on ATR–CHK1 and ATR–NBS1–FANCD2 pathways. *The EMBO journal*. 2004;23(5):1178-87.
- [20] Andreassen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. *Genes & development*. 2004;18(16):1958-63.
- [21] Ho GP, Margossian S, Taniguchi T, D'Andrea AD. Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. *Molecular and cellular biology*. 2006;26(18):7005-15.
- [22] Ishiai M, Kitao H, Smogorzewska A, Tomida J, Kinomura A, Uchida E, et al. FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. *Nature structural & molecular biology*. 2008;15(11):1138-46.
- [23] Collins NB, Wilson JB, Bush T, Thomashevski A, Roberts KJ, Jones NJ, et al. ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function. *Blood*. 2009;113(10):2181-90.
- [24] Wang X, Kennedy RD, Ray K, Stuckert P, Ellenberger T, D'Andrea AD. Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. *Molecular and cellular biology*. 2007;27(8):3098-108.
- [25] Singh TR, Ali AM, Paramasivam M, Pradhan A, Wahengbam K, Seidman MM, et al. ATR-dependent phosphorylation of FANCM at serine 1045 is essential for FANCM functions. *Cancer research*. 2013;73(14):4300-10.
- [26] Pulsipher M, Kupfer GM, Naf D, Suliman A, Lee J-S, Jakobs P, et al. Subtyping analysis of Fanconi anemia by immunoblotting and retroviral gene transfer. *Molecular Medicine*. 1998;4(7):468.

- [27] Garcia-Higuera I, Kuang Y, Näf D, Wasik J, D'Andrea AD. Fanconi anemia proteins FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear complex. *Molecular and Cellular Biology*. 1999;19(7):4866-73.
- [28] Kupfer GM, Näf D, Suliman A, Pulsipher M, D'Andrea AD. The Fanconi anaemia proteins, FAA and FAC interact to form a nuclear complex. *Nature genetics*. 1997;17(4):487-90.
- [29] Medhurst AL, Laghmani EH, Steltenpool J, Ferrer M, Fontaine C, de Groot J, et al. Evidence for subcomplexes in the Fanconi anemia pathway. *Blood*. 2006;108(6):2072-80.
- [30] Polito D, Cukras S, Wang X, Spence P, Moreau L, D'Andrea AD, et al. The Carboxyl Terminus of FANCE Recruits FANCD2 to the Fanconi Anemia (FA) E3 Ligase Complex to Promote the FA DNA Repair Pathway. *Journal of Biological Chemistry*. 2014;289(10):7003-10.
- [31] Garcia-Higuera I, Kuang Y, Denham J, D'Andrea AD. The Fanconi anemia proteins FANCA and FANCG stabilize each other and promote the nuclear accumulation of the Fanconi anemia complex. *Blood*. 2000;96(9):3224-30.
- [32] Medhurst AL, Huber PA, Waisfisz Q, de Winter JP, Mathew CG. Direct interactions of the five known Fanconi anaemia proteins suggest a common functional pathway. *Human Molecular Genetics*. 2001;10(4):423-9.
- [33] Taniguchi T, D'Andrea AD. The Fanconi anemia protein, FANCE, promotes the nuclear accumulation of FANCC. *Blood*. 2002;100(7):2457-62.
- [34] Näf D, Kupfer GM, Suliman A, Lambert K, D'Andrea AD. Functional activity of the Fanconi anemia protein FAA requires FAC binding and nuclear localization. *Molecular and Cellular Biology*. 1998;18(10):5952-60.
- [35] Ling C, Ishiai M, Ali AM, Medhurst AL, Neveling K, Kalb R, et al. FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. *The EMBO journal*. 2007;26(8):2104-14.
- [36] Leung JWC, Wang Y, Fong KW, Huen MSY, Li L, Chen J. Fanconi anemia (FA) binding protein FAAP20 stabilizes FA complementation group A (FANCA) and participates in interstrand cross-link repair. *Proceedings of the National Academy of Sciences*. 2012;109(12):4491-6.
- [37] Rajendra E, Oestergaard VH, Langevin F, Wang M, Dornan GL, Patel KJ, et al. The Genetic and Biochemical Basis of FANCD2 Monoubiquitination. *Molecular Cell*. 2014;54(5):858-69.
- [38] Huang Y, Leung JW, Lowery M, Matsushita N, Wang Y, Shen X, et al. Modularized Functions of the Fanconi Anemia Core Complex. *Cell Reports*. 2014.

- [39] Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. *Molecular cell*. 2001;7(2):249-62.
- [40] Meetei AR, Yan Z, Wang W. FANCL replaces BRCA1 as the likely ubiquitin ligase responsible for FANCD2 monoubiquitination. *CELL CYCLE-LANDES BIO-SCIENCE*-. 2004;3(2):179-81.
- [41] Meetei AR, de Winter JP, Medhurst AL, Wallisch M, Waisfisz Q, Van de Vrugt HJ, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. *Nature genetics*. 2003;35(2):165-70.
- [42] Cole AR, Lewis LP, Walden H. The structure of the catalytic subunit FANCL of the Fanconi anemia core complex. *Nature structural & molecular biology*. 2010;17(3):294-8.
- [43] Alpi AF, Pace PE, Babu MM, Patel KJ. Mechanistic insight into site-restricted monoubiquitination of FANCD2 by Ube2t, FANCL, and FANCI. *Molecular cell*. 2008;32(6):767-77.
- [44] Machida YJ, Machida Y, Chen Y, Gurtan AM, Kupfer GM, D'Andrea AD, et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. *Molecular cell*. 2006;23(4):589-96.
- [45] Smogorzewska A, Matsuoka S, Vinciguerra P, McDonald III ER, Hurov KE, Luo J, et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. *Cell*. 2007;129(2):289-301.
- [46] Dorsman JC, Levitus M, Rockx D, Rooimans MA, Oostra AB, Haitjema A, et al. Identification of the Fanconi anemia complementation group I gene, FANCI. *Analytical Cellular Pathology*. 2007;29(3):211-8.
- [47] Sims A, Spiteri E, Sims 3rd R, Arita A, Lach F, Landers T, et al. FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. *Nature structural & molecular biology*. 2007;14(6):564.
- [48] Joo W, Xu G, Persky NS, Smogorzewska A, Rudge DG, Buzovetsky O, et al. Structure of the FANCI-FANCD2 complex: insights into the Fanconi anemia DNA repair pathway. *Science*. 2011;333(6040):312-6.
- [49] Longerich S, San Filippo J, Liu D, Sung P. FANCI binds branched DNA and is monoubiquitinated by UBE2T-FANCL. *Journal of Biological Chemistry*. 2009;284(35):23182-6.
- [50] Longerich S, Kwon Y, Tsai M-S, Hlaing AS, Kupfer GM, Sung P. Regulation of FANCD2 and FANCI monoubiquitination by their interaction and by DNA. *Nucleic acids research*. 2014;42(9):5657-70.

- [51] Sato K, Toda K, Ishiai M, Takata M, Kurumizaka H. DNA robustly stimulates FANCD2 monoubiquitylation in the complex with FANCI. *Nucleic acids research*. 2012;40(10):4553-61.
- [52] Sareen A, Chaudhury I, Adams N, Soback A. Fanconi anemia proteins FANCD2 and FANCI exhibit different DNA damage responses during S-phase. *Nucleic acids research*. 2012;40(17):8425-39.
- [53] Nijman S, Huang TT, Dirac AM, Brummelkamp TR, Kerkhoven RM, D'Andrea AD, et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. *Molecular cell*. 2005;17(3):331-9.
- [54] Oestergaard VH, Langevin F, Kuiken HJ, Pace P, Niedzwiedz W, Simpson LJ, et al. Deubiquitination of FANCD2 is required for DNA crosslink repair. *Molecular cell*. 2007;28(5):798-809.
- [55] Murai J, Yang K, Dejsuphong D, Hirota K, Takeda S, D'Andrea AD. The USP1/UAF1 complex promotes double-strand break repair through homologous recombination. *Molecular and cellular biology*. 2011;31(12):2462-9.
- [56] Cohn MA, Kowal P, Yang K, Haas W, Huang TT, Gygi SP, et al. A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. *Molecular cell*. 2007;28(5):786-97.
- [57] Yang K, Moldovan G-L, Vinciguerra P, Murai J, Takeda S, D'Andrea AD. Regulation of the Fanconi anemia pathway by a SUMO-like delivery network. *Genes & development*. 2011;25(17):1847-58.
- [58] Park E, Kim JM, Primack B, Weinstock DM, Moreau LA, Parmar K, et al. Inactivation of Uaf1 Causes Defective Homologous Recombination and Early Embryonic Lethality in Mice. *Molecular and cellular biology*. 2013;33(22):4360-70.
- [59] Kim JM, Parmar K, Huang M, Weinstock DM, Ruit CA, Kutok JL, et al. Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. *Developmental cell*. 2009;16(2):314-20.
- [60] Bunting SF, Callén E, Kozak ML, Kim JM, Wong N, López-Contreras AJ, et al. BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. *Molecular cell*. 2012;46(2):125-35.
- [61] Bhagwat N, Olsen AL, Wang AT, Hanada K, Stuckert P, Kanaar R, et al. XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair. *Molecular and cellular biology*. 2009;29(24):6427-37.
- [62] Bogliolo M, Lyakhovich A, Callén E, Castellà M, Cappelli E, Ramírez MJ, et al. Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability. *The EMBO journal*. 2007;26(5):1340-51.

- [63] Wang CQ, Krishnan V, Tay LS, Chin DWL, Koh CP, Chooi JY, et al. Disruption of *Runx1* and *Runx3* Leads to Bone Marrow Failure and Leukemia Predisposition due to Transcriptional and DNA Repair Defects. *Cell reports*. 2014;8(3):767-82.
- [64] Click ES, Cox B, Olson SB, Grompe M, Akkari Y, Moreau LA, et al. Fanconi anemia-like presentation in an infant with constitutional deletion of 21q including the *RUNX1* gene. *American Journal of Medical Genetics Part A*. 2011;155(7):1673-9.
- [65] Byrd RS, Zwerdling T, Moghaddam B, Pinter JD, Steinfeld MB. Monosomy 21q22. 11-q22. 13 presenting as a Fanconi anemia phenotype. *American Journal of Medical Genetics Part A*. 2011;155(1):120-5.
- [66] Chen X, Wilson JB, McChesney P, Williams SA, Kwon Y, Longerich S, et al. The Fanconi Anemia Proteins FANCD2 and FANCI Interact and Regulate Each Other's Chromatin Localization. *Journal of Biological Chemistry*. 2014;289(37):25774-82.
- [67] Crossan GP, Patel KJ. The Fanconi anaemia pathway orchestrates incisions at sites of crosslinked DNA. *The Journal of pathology*. 2012;226(2):326-37.
- [68] Smogorzewska A, Desetty R, Saito TT, Schlabach M, Lach FP, Sowa ME, et al. A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. *Molecular cell*. 2010;39(1):36-47.
- [69] Liu T, Ghosal G, Yuan J, Chen J, Huang J. FAN1 acts with FANCI-FANCD2 to promote DNA interstrand cross-link repair. *Science*. 2010;329(5992):693-6.
- [70] MacKay C, Déclais A-C, Lundin C, Agostinho A, Deans AJ, MacArtney TJ, et al. Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. *Cell*. 2010;142(1):65-76.
- [71] Stoepker C, Hain K, Schuster B, Hilhorst-Hofstee Y, Rooimans MA, Steltenpool J, et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. *Nature genetics*. 2011;43(2):138-41.
- [72] Crossan GP, van der Weyden L, Rosado IV, Langevin F, Gaillard P-HL, McIntyre RE, et al. Disruption of mouse *Slx4*, a regulator of structure-specific nucleases, phenocopies Fanconi anemia. *Nature genetics*. 2011;43(2):147-52.
- [73] Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A. Mutations of the *SLX4* gene in Fanconi anemia. *Nature genetics*. 2011;43(2):142-6.
- [74] Bogliolo M, Schuster B, Stoepker C, Derkunt B, Su Y, Raams A, et al. Mutations in *ERCC4*, Encoding the DNA-Repair Endonuclease XPF, Cause Fanconi Anemia. *The American Journal of Human Genetics*. 2013;92(5):800-6.
- [75] Svendsen JM, Smogorzewska A, Sowa ME, O'Connell BC, Gygi SP, Elledge SJ, et al. Mammalian *BTBD12/SLX4* assembles a Holliday junction resolvase and is required for DNA repair. *Cell*. 2009;138(1):63-77.

- [76] Yamamoto KN, Kobayashi S, Tsuda M, Kurumizaka H, Takata M, Kono K, et al. Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway. *Proceedings of the National Academy of Sciences*. 2011;108(16):6492-6.
- [77] Hodskinson MR, Silhan J, Crossan GP, Garaycochea JI, Mukherjee S, Johnson CM, et al. Mouse SLX4 Is a Tumor Suppressor that Stimulates the Activity of the Nuclease XPF-ERCC1 in DNA Crosslink Repair. *Molecular cell*. 2014;54(3):472-84.
- [78] Kim Y, Spitz GS, Veturi U, Lach FP, Auerbach AD, Smogorzewska A. Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4. *Blood*. 2013;121(1):54-63.
- [79] Klein Douwel D, Boonen RA, Long DT, Szypowska AA, Räsche M, Walter JC, et al. XPF-ERCC1 Acts in Unhooking DNA Interstrand Crosslinks in Cooperation with FANCD2 and FANCP/SLX4. *Molecular cell*. 2014;54(3):460-71.
- [80] Fisher LA, Bessho M, Bessho T. Processing of a psoralen DNA interstrand cross-link by XPF-ERCC1 complex in vitro. *Journal of Biological Chemistry*. 2008;283(3):1275-81.
- [81] Wang AT, Sengerová B, Cattell E, Inagawa T, Hartley JM, Kiakos K, et al. Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair. *Genes & development*. 2011;25(17):1859-70.
- [82] Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, de Die-Smulders C, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. *Science*. 2002;297(5581):606-9.
- [83] Wang X, Andreassen PR, D'Andrea AD. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. *Molecular and cellular biology*. 2004;24(13):5850-62.
- [84] Levitus M, Waisfisz Q, Godthelp BC, de Vries Y, Hussain S, Wiegant WW, et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. *Nature genetics*. 2005;37(9):934-5.
- [85] Litman R, Peng M, Jin Z, Zhang F, Zhang J, Powell S, et al. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCF. *Cancer cell*. 2005;8(3):255-65.
- [86] Shen X, Do H, Li Y, Chung W-H, Tomasz M, de Winter JP, et al. Recruitment of fanconi anemia and breast cancer proteins to DNA damage sites is differentially governed by replication. *Molecular cell*. 2009;35(5):716-23.
- [87] Cantor S, Drapkin R, Zhang F, Lin Y, Han J, Pamidi S, et al. The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. *Proceedings of the National Academy of Sciences of the United States of America*. 2004;101(8):2357-62.

- [88] Bridge WL, Vandenberg CJ, Franklin RJ, Hiom K. The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair. *Nature genetics*. 2005;37(9):953-7.
- [89] Peng M, Litman R, Xie J, Sharma S, Brosh RM, Cantor SB. The FANCDJ/MutL α interaction is required for correction of the cross-link response in FA-J cells. *The EMBO journal*. 2007;26(13):3238-49.
- [90] Somyajit K, Subramanya S, Nagaraju G. Distinct roles of Fanco/RAD51C protein in DNA damage signaling and repair implications for fanconi anemia and breast cancer susceptibility. *Journal of Biological Chemistry*. 2012;287(5):3366-80.
- [91] Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. *Nature genetics*. 2010;42(5):406-9.
- [92] Park J, Singh T, Nassar N, Zhang F, Freund M, Hanenberg H, et al. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair. *Oncogene*. 2013.
- [93] Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. *Nature genetics*. 2006;39(2):162-4.
- [94] Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. *Nature genetics*. 2006;39(2):159-61.
- [95] Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B, et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. *Current Biology*. 2009;19(6):524-9.
- [96] Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. *Molecular cell*. 2006;22(6):719-29.
- [97] Sy SM, Huen MS, Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. *Proceedings of the National Academy of Sciences*. 2009;106(17):7155-60.
- [98] Chang DJ, Cimprich KA. DNA damage tolerance: when it's OK to make mistakes. *Nature chemical biology*. 2009;5(2):82-90.
- [99] Papadopoulou D, Guillouf C, Mohrenweiser H, Moustacchi E. Hypomutability in Fanconi anemia cells is associated with increased deletion frequency at the HPRT locus. *Proceedings of the National Academy of Sciences*. 1990;87(21):8383-7.
- [100] Sharma S, Canman CE. REV1 and DNA polymerase zeta in DNA interstrand cross-link repair. *Environmental and molecular mutagenesis*. 2012;53(9):725-40.
- [101] Kim H, Yang K, Dejsuphong D, D'Andrea A. Regulation of Rev1 by the Fanconi anemia core complex. *Nature structural & molecular biology*. 2012;19(2):164-70.

- [102] Geng L, Huntoon CJ, Karnitz LM. RAD18-mediated ubiquitination of PCNA activates the Fanconi anemia DNA repair network. *The Journal of cell biology*. 2010;191(2):249-57.
- [103] Murina O, von Aesch C, Karakus U, Ferretti LP, Bolck HA, Hänggi K, et al. FANCD2 and CtIP Cooperate to Repair DNA Interstrand Crosslinks. *Cell reports*. 2014;7(4):1030-8.
- [104] Unno J, Itaya A, Taoka M, Sato K, Tomida J, Sakai W, et al. FANCD2 Binds CtIP and Regulates DNA-End Resection during DNA Interstrand Crosslink Repair. *Cell reports*. 2014;7(4):1039-47.
- [105] Yeo JE, Lee EH, Hendrickson E, Soback A. CtIP mediates replication fork recovery in a FANCD2-regulated manner. *Human molecular genetics*. 2014:ddu078.
- [106] Nakanishi K, Cavallo F, Perrouault L, Giovannangeli C, Moynahan ME, Barchi M, et al. Homology-directed Fanconi anemia pathway cross-link repair is dependent on DNA replication. *Nature structural & molecular biology*. 2011;18(4):500-3.
- [107] Pace P, Mosedale G, Hodkinson MR, Rosado IV, Sivasubramaniam M, Patel KJ. Ku70 corrupts DNA repair in the absence of the Fanconi anemia pathway. *Science*. 2010;329(5988):219-23.
- [108] Adamo A, Collis SJ, Adelman CA, Silva N, Horejsi Z, Ward JD, et al. Preventing non-homologous end joining suppresses DNA repair defects of Fanconi anemia. *Molecular cell*. 2010;39(1):25-35.
- [109] Yu HS, Oyama T, Matsuda T, Isse T, Yamaguchi T, Tanaka M, et al. The effect of ethanol on the formation of N2-ethylidene-dG adducts in mice: implications for alcohol-related carcinogenicity of the oral cavity and esophagus. *Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals*. 2012;17(3):269-74.
- [110] Yukawa Y, Muto M, Hori K, Nagayoshi H, Yokoyama A, Chiba T, et al. Combination of ADH1B* 2/ALDH2* 2 polymorphisms alters acetaldehyde-derived DNA damage in the blood of Japanese alcoholics. *Cancer science*. 2012;103(9):1651-5.
- [111] Yukawa Y, Ohashi S, Amanuma Y, Nakai Y, Tsurumaki M, Kikuchi O, et al. Impairment of aldehyde dehydrogenase 2 increases accumulation of acetaldehyde-derived DNA damage in the esophagus after ethanol ingestion. *American journal of cancer research*. 2014;4(3):279-84.
- [112] Garaycochea JL, Crossan GP, Langevin F, Daly M, Arends MJ, Patel KJ. Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. *Nature*. 2012;489(7417):571-5.
- [113] Rosado IV, Langevin F, Crossan GP, Takata M, Patel KJ. Formaldehyde catabolism is essential in cells deficient for the Fanconi anemia DNA-repair pathway. *Nature structural & molecular biology*. 2011;18(12):1432-4.

- [114] Oberbeck N, Langevin F, King G, de Wind N, Crossan GP, Patel KJ. Maternal Aldehyde Elimination during Pregnancy Preserves the Fetal Genome. *Molecular cell*. 2014;55(6):807-17.
- [115] Schlacher K, Wu H, Jasin M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. *Cancer cell*. 2012;22(1):106-16.
- [116] Chaudhury I, Sareen A, Raghunandan M, Sobeck A. FANCD2 regulates BLM complex functions independently of FANCI to promote replication fork recovery. *Nucleic acids research*. 2013;41(13):6444-59.
- [117] Chaudhury I, Stroik DR, Sobeck A. FANCD2-controlled chromatin access of the Fanconi-associated nuclease FAN1 is crucial for the recovery of stalled replication forks. *Molecular and cellular biology*. 2014;34(21):3939-54.
- [118] Sirbu BM, McDonald WH, Dungrawala H, Badu-Nkansah A, Kavanaugh GM, Chen Y, et al. Identification of proteins at active, stalled, and collapsed replication forks using Isolation of proteins on nascent DNA (iPOND) coupled with mass spectrometry. *Journal of Biological Chemistry*. 2013;288(44):31458-67.
- [119] Blackford AN, Schwab RA, Nieminszczy J, Deans AJ, West SC, Niedzwiedz W. The DNA translocase activity of FANCM protects stalled replication forks. *Human molecular genetics*. 2012;21(9):2005-16.
- [120] Luebben SW, Kawabata T, Johnson CS, O'Sullivan MG, Shima N. A concomitant loss of dormant origins and FANCC exacerbates genome instability by impairing DNA replication fork progression. *Nucleic acids research*. 2014;42(9):5605-15.
- [121] Lossaint G, Larroque M, Ribeyre C, Bec N, Larroque C, Décaillot C, et al. FANCD2 binds MCM proteins and controls replisome function upon activation of S phase checkpoint signaling. *Molecular cell*. 2013;51(5):678-90.
- [122] Park E, Kim H, Kim JM, Primack B, Vidal-Cardenas S, Xu Y, et al. FANCD2 activates transcription of TAp63 and suppresses tumorigenesis. *Molecular cell*. 2013;50(6):908-18.
- [123] Matsushita N, Endo Y, Sato K, Kurumizaka H, Yamashita T, Takata M, et al. Direct inhibition of TNF- α promoter activity by Fanconi anemia protein FANCD2. *PloS one*. 2011;6(8):e23324.
- [124] Nguyen TV, Riou L, Aoufouchi S, Rosselli F. Fanca deficiency reduces A/T transitions in somatic hypermutation and alters class switch recombination junctions in mouse B cells. *The Journal of experimental medicine*. 2014;jem. 20131637.
- [125] Naim V, Rosselli F. The FANC pathway and BLM collaborate during mitosis to prevent micro-nucleation and chromosome abnormalities. *Nature cell biology*. 2009;11(6):761-8.

- [126] Vinciguerra P, Godinho SA, Parmar K, Pellman D, D'Andrea AD. Cytokinesis failure occurs in Fanconi anemia pathway-deficient murine and human bone marrow hemopoietic cells. *The Journal of clinical investigation*. 2010;120(11):3834-42.
- [127] Rosenberg PS, Huang Y, Alter BP. Individualized risks of first adverse events in patients with Fanconi anemia. *Blood*. 2004;104(2):350-5.
- [128] Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). *Blood*. 2003;101(4):1249-56.
- [129] Alter BP. Cancer in Fanconi anemia, 1927-2001. *Cancer*. 2003;97(2):425-40.
- [130] Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. *Blood*. 2003;101(3):822-6.
- [131] Butturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio A, Auerbach A. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study [see comments]. *Blood*. 1994;84(5):1650-5.
- [132] Hirsch B, Shimamura A, Moreau L, Baldinger S, Hag-alshiekh M, Bostrom B, et al. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. *Blood*. 2004;103(7):2554-9.
- [133] Alter BP, Rosenberg PS, Brody LC. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. *Journal of medical genetics*. 2007;44(1):1-9.
- [134] Whitney M, Royle G, Low MJ, Kelly M, Axthelm M, Reifsteck C, et al. Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in mice with a targeted disruption of the Fanconi anemia C gene. *Blood*. 1996;88(1):49-58.
- [135] Cheng NC, van de Vrugt HJ, van der Valk MA, Oostra AB, Krimpenfort P, de Vries Y, et al. Mice with a targeted disruption of the Fanconi anemia homolog Fanca. *Human molecular genetics*. 2000;9(12):1805-11.
- [136] Wong JC, Alon N, Mckerlie C, Huang JR, Meyn MS, Buchwald M. Targeted disruption of exons 1 to 6 of the Fanconi Anemia group A gene leads to growth retardation, strain-specific microphthalmia, meiotic defects and primordial germ cell hypoplasia. *Human molecular genetics*. 2003;12(16):2063-76.
- [137] Yang Y, Kuang Y, De Oca RM, Hays T, Moreau L, Lu N, et al. Targeted disruption of the murine Fanconi anemia gene, *Fancg/Xrcc9*. *Blood*. 2001;98(12):3435-40.
- [138] Koomen M, Cheng NC, van de Vrugt HJ, Godthelp BC, van der Valk MA, Oostra AB, et al. Reduced fertility and hypersensitivity to mitomycin C characterize *Fancg/Xrcc9* null mice. *Human Molecular Genetics*. 2002;11(3):273-81.
- [139] Carreau M, Gan OI, Liu L, Doedens M, McKerlie C, Dick JE, et al. Bone marrow failure in the Fanconi anemia group C mouse model after DNA damage. *Blood*. 1998;91(8):2737-44.

- [140] Pulliam-Leath AC, Ciccone SL, Nalepa G, Li X, Si Y, Miravalle L, et al. Genetic disruption of both *Fancc* and *Fancg* in mice recapitulates the hematopoietic manifestations of Fanconi anemia. *Blood*. 2010;116(16):2915-20.
- [141] Houghtaling S, Timmers C, Noll M, Finegold MJ, Jones SN, Meyn MS, et al. Epithelial cancer in Fanconi anemia complementation group D2 (*Fancd2*) knockout mice. *Genes & development*. 2003;17(16):2021-35.
- [142] Houghtaling S, Granville L, Akkari Y, Torimaru Y, Olson S, Finegold M, et al. Heterozygosity for p53 (*Trp53*^{+/-}) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (*Fancd2*) knockout mice. *Cancer research*. 2005;65(1):85-91.
- [143] Langevin F, Crossan GP, Rosado IV, Arends MJ, Patel KJ. *Fancd2* counteracts the toxic effects of naturally produced aldehydes in mice. *Nature*. 2011;475(7354):53-8.
- [144] Bakker ST, van de Vrugt HJ, Rooimans MA, Oostra AB, Steltenpool J, Delzenne-Goette E, et al. *Fancm*-deficient mice reveal unique features of Fanconi anemia complementation group M. *Human molecular genetics*. 2009;18(18):3484-95.
- [145] Bakker ST, van de Vrugt HJ, Visser JA, Delzenne-Goette E, van der Wal A, Berns MA, et al. *Fancf*-deficient mice are prone to develop ovarian tumours. *The Journal of pathology*. 2012;226(1):28-39.
- [146] Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of *Brca1*, *Brca2*, *Brca1/Brca2*, *Brca1/p53*, and *Brca2/p53* nullizygous embryos. *Genes & development*. 1997;11(10):1226-41.
- [147] Kuznetsov S, Pellegrini M, Shuda K, Fernandez-Capetillo O, Liu Y, Martin BK, et al. RAD51C deficiency in mice results in early prophase I arrest in males and sister chromatid separation at metaphase II in females. *The Journal of cell biology*. 2007;176(5):581-92.
- [148] Simhadri S, Peterson S, Patel DS, Huo Y, Cai H, Bowman-Colin C, et al. Male fertility defect associated with disrupted BRCA1-PALB2 interaction in mice. *Journal of Biological Chemistry*. 2014;289(35):24617-29.
- [149] Friedman LS, Thistlethwaite FC, Petel KJ, Veronica P, Lee H, Venkitaraman AR, et al. Thymic lymphomas in mice with a truncating mutation in *Brca2*. *Cancer research*. 1998;58(7):1338-43.
- [150] McAllister KA, Bennett LM, Houle CD, Ward T, Malphurs J, Collins NK, et al. Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the *Brca2* gene. *Cancer research*. 2002;62(4):990-4.
- [151] Donoho G, Brenneman MA, Cui TX, Donoviel D, Vogel H, Goodwin EH, et al. Deletion of *Brca2* exon 27 causes hypersensitivity to DNA crosslinks, chromosomal insta-

bility, and reduced life span in mice. *Genes, Chromosomes and Cancer*. 2003;36(4):317-31.

- [152] Stewart G, Elledge SJ. The two faces of BRCA2, a FANCTastic discovery. *Molecular cell*. 2002;10(1):2-4.
- [153] Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, et al. Mutations in BRIP1 confer high risk of ovarian cancer. *Nature genetics*. 2011;43(11):1104-7.
- [154] Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. *Nature genetics*. 2010;42(5):410-4.
- [155] Vuorela M, Pylkäs K, Hartikainen JM, Sundfeldt K, Lindblom A, von Wachenfeldt Wäppling A, et al. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility. *Breast cancer research and treatment*. 2011;130(3):1003-10.
- [156] Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, et al. RAD51C is a susceptibility gene for ovarian cancer. *Human molecular genetics*. 2011;ddr229.
- [157] Coulet F, Fajac A, Colas C, Eyries M, Dion-Minière A, Rouzier R, et al. Germline RAD51C mutations in ovarian cancer susceptibility. *Clinical genetics*. 2013;83(4):332-6.
- [158] Poupouridou N, Kroupis C. Hereditary breast cancer: beyond BRCA genetic analysis; PALB2 emerges. *Clinical Chemistry and Laboratory Medicine*. 2012;50(3):423-34.
- [159] Zheng Y, Zhang J, Niu Q, Huo D, Olopade OI. Novel germline PALB2 truncating mutations in African American breast cancer patients. *Cancer*. 2012;118(5):1362-70.
- [160] Litim N, Labrie Y, Desjardins S, Ouellette G, Plourde K, Belleau P, et al. Polymorphic variations in the FANCA gene in high-risk non-*> BRCA1/2</i> breast cancer individuals from the French Canadian population. *Molecular oncology*. 2013;7(1):85-100.*
- [161] Kiiski JL, Pelttari LM, Khan S, Freysteinsdottir ES, Reynisdottir I, Hart SN, et al. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. *Proceedings of the National Academy of Sciences*. 2014;111(42):15172-7.
- [162] van der Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. *Cancer research*. 2003;63(10):2585-8.
- [163] Rogers CD, van der Heijden MS, Brune K, Yeo CJ, Hruban RH, Kern SE, et al. The genetics of FANCC and FANCG in familial pancreatic cancer. *Cancer Biology and Therapy*. 2004;3(2):167-9.

- [164] Couch FJ, Johnson MR, Rabe K, Boardman L, McWilliams R, de Andrade M, et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. *Cancer research*. 2005;65(2):383-6.
- [165] Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. *Oncogene*. 2003;23(4):1000-4.
- [166] Lim S, Smith P, Syed N, Coens C, Wong H, van der Burg M, et al. Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. *British journal of cancer*. 2008;98(8):1452-6.
- [167] Li N, Zhang F, Li S, Zhou S. Epigenetic silencing of MicroRNA-503 regulates FANCA expression in non-small cell lung cancer cell. *Biochemical and biophysical research communications*. 2014;444(4):611-6.
- [168] Ghosh A, Ghosh S, Maiti GP, Mukherjee S, Mukherjee N, Chakraborty J, et al. Association of FANCC and PTCH1 with the development of early dysplastic lesions of the head and neck. *Annals of surgical oncology*. 2012;19(3):528-38.
- [169] Szaumkessel M, Richter J, Giefing M, Jarmuz M, Kiwerska K, Tönnies H, et al. Pyrosequencing-based DNA methylation profiling of Fanconi anemia/BRCA pathway genes in laryngeal squamous cell carcinoma. *International journal of oncology*. 2011;39(2):505.
- [170] Hess C, Ameziane N, Schuurhuis G, Errami A, Denkers F, Kaspers G, et al. Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. *Analytical Cellular Pathology*. 2008;30(4):299-306.
- [171] Potapova A, Hoffman AM, Godwin AK, Al-Saleem T, Cairns P. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. *Cancer research*. 2008;68(4):998-1002.
- [172] Wei M, Xu J, Dignam J, Nanda R, Sveen L, Fackenthal J, et al. Estrogen receptor α , BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. *Breast cancer research and treatment*. 2008;111(1):113-20.
- [173] Wang Z, Li M, Lu S, Zhang Y, Wang H. Research Paper Promoter Hypermethylation of FANCF Plays an Important Role in the Occurrence of Ovarian Cancer through Disrupting Fanconi Anemia-BRCA Pathway. *Cancer biology & therapy*. 2006;5(3):256-60.
- [174] Olopade OI, Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. *Cancer cell*. 2003;3(5):417-20.
- [175] Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, et al. Promoter hypermethylation of FANCF disruption of Fanconi Anemia-BRCA pathway in cervical cancer. *Cancer research*. 2004;64(9):2994-7.

- [176] Tischkowitz M, Ameziane N, Waisfisz Q, De Winter JP, Harris R, Taniguchi T, et al. Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. *British journal of haematology*. 2003;123(3):469-71.
- [177] Gravelles P, Hoh L, Solovieva S, Patil A, Dudzicz E, Rennie I, et al. Reduced FANCD2 influences spontaneous SCE and RAD51 foci formation in uveal melanoma and Fanconi anaemia. *Oncogene*. 2013;32(46):5338-46.
- [178] Sinha S, Singh RK, Alam N, Roy A, Roychoudhury S, Panda CK. Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22. 3 region: pathological significance in early-and late-onset breast carcinoma. *Mol Cancer*. 2008;7(84):10.1186.
- [179] Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer discovery*. 2012;2(5):401-4.
- [180] Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Science signaling*. 2013;6(269):p11.